For investors

TG Pharma is a preclinical stage SPV company developing a novel therapy for the treatment of diseases associated with the prevalence of Demodex spp. The global market value for the treatment of blepharitis, dry eye disease and rosacea is estimated at over USD 6 billion. Demodex mites are found in 55-70% of patients diagnosed with these conditions. However, the majority of patients are misdiagnosed. Moreover, no effective treatment is available. We are targeting this huge number of underdiagnosed cases.

If you are interested in learning more about Demophta, potential investment opportunities or partnering, please contact our Business Development Manager, Viktoria Babenko.